Adalimumab Effective for Crohn’s Disease

Effective for Crohn’s Disease

n a double blind, multicenter trial in the Netherlands, researchers evaluated 76 adults with Crohn’s disease (CD) and perianal fistulizing disease treated with adalimumab once every 2 weeks along with either placebo (n=39) or 500 mg (CIP, n=37) twice daily for 12 weeks. Adalimumab was continued until completion of follow-up at 24 weeks. Dosing for adalimumab began at 160 mg, was reduced to 80 mg at 2 weeks and then to 40 mg for the remainder of the study. All participants were evaluated according to the Perianal Disease Activity Index (PDAI), Crohn’s Disease Activity Index (CDAI) and IBD Questionnaire (IBDQ) at baseline and at 12 and 24 weeks.

Adalimumab/ciprofloxacin effective for Crohn’s disease-related perianal

In a double blind, multicenter trial in the Netherlands, researchers evaluated 76 adults with Crohn’s disease (CD) and perianal fistulizing disease treated with adalimumab once every 2 weeks along with either placebo (n=39) or 500 mg ciprofloxacin (CIP

Adalimumab/ciprofloxacin effective for Crohn’s disease-related perianal fistula closure

Leave a Reply